Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Diagnos Inc V.ADK

Alternate Symbol(s):  DGNOF

Diagnos Inc. is a Canadian company, which is engaged in early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications, such as computer assisted retina analysis (CARA). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a tool for real-time screening of large volumes of patients. It provides software-based services to assist health specialists in the detection of diabetic retinopathy and other eye-related pathologies. Its geographical areas include Canada, the United States of America, Mexico, and Chile. The Company’s subsidiaries include Diagnos Internacional SA de CV and Diagnos Healthcare (India) Private Limited.


TSXV:ADK - Post by User

Bullboard Posts
Post by u2bobon Mar 13, 2019 9:56am
127 Views
Post# 29477896

NR

NRDIAGNOS Announces New Agreement in the United Arab Emirates with one of the Largest Pharmaceutical Companies in the World March 13, 2019 09:44 ET|Source:DIAGNOS Inc. multilang-release BROSSARD, Quebec, March 13, 2019 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (DIAGNOS or the Corporation) (TSX Venture: ADK), (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today the signing of a significant renewal contract in the United Arab Emirates consisting of a turnkey one-year screening contract for 2 CARA platform services. So far, DIAGNOS healthcare services have been rendered in 16 countries worldwide. During the period covered by the agreement, DIAGNOS estimates that an additional 5,000 patients will be screened in UAE using its CARA platform. We are excited to continue our collaboration with one of the largest pharmaceutical companies in the world. More and more, we, DIAGNOS and our strategic pharmaceutical partner, are educating governments around the world to our Wellness Program (CARA) and demonstrating the benefits and tremendous cost savings that can be attained from it. We also continue to implement our growth strategy withthis keypharmaceutical partner, said Andr Larente, President of DIAGNOS.
Bullboard Posts